Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
78.50
-1.50 (-1.88%)
Jan 28, 2026, 5:00 PM CET
-5.08%
Market Cap393.96M
Revenue (ttm)n/a
Net Income-14.79M
EPS-2.89
Shares Out4.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,510
Average Volume6,805
Open80.50
Previous Close80.00
Day's Range78.50 - 80.50
52-Week Range73.00 - 129.00
Beta1.19
RSI46.35
Earnings DateApr 28, 2026

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements